1 of 1
Story summary
- Dexcom, Inc. reported revenue of $4.7 billion in the last fiscal year, marking a 16% increase.
- Its earnings per share rose to $2.09, up from $1.42 the previous year.
- Dexcom faces GLP-1 weight loss competition, but is expanding its market.
- Only 1% of diabetes patients currently use CGMs, indicating growth potential.
- Dexcom launched Stelo, an over-the-counter CGM for prediabetic patients, broadening its customer base.
